Blog


Posaconazole

Posaconazole CAS No:171228-49-2 Posaconazole is a type of oral triazole antifungal API that has shown a high rate of efficacy for a number of fungal conditions without the risk of severe side effects. While many antifungal medications have ostensibly similar jobs, each one has their own limitations and patient disadvantages. Posaconazole was developed as an[…]

Read More

Dermatological Antifungal

The dermatological antifungal segment has three more FDA approved options. This is good news for a specialty area that could use more diversity when it comes to treating fungal infections. Tavaborole and Efinaconazole were both approved by the FDA in 2014 to treat fungi of the nail and nailbeds, and Crisaborole was approved in 2016[…]

Read More

AAPS Banner

The 2017 AAPS Annual Meeting and Exposition took place in San Diego November 12-15. It brought together more than 6,100 scientists, business leaders, government officials, and students from around the world to share and learn the latest scientific advances and industry developments. The meeting featured 100 scientific sessions and 2,200 posters, workshops, and short courses.[…]

Read More

New Harbor Capital

Chicago-based private equity firm New Harbor Capital completed a majority equity investment in LGM Pharma, an innovation-driven company involved in distribution of cGMP active pharmaceutical ingredients (“API”) and other value-added services supporting leading pharmaceutical companies. LGM specializes in streamlining the API supply chain throughout all development stages while providing complete technical capabilities and expert regulatory[…]

Read More

Andrew Mitrani headshot

NASHVILLE, Tennessee – LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Nashville, Tennessee with administrative offices in Boca Raton, Florida, recently announced that Mr. Andrew Mitrani would be joining the organization as the Associate Director of Business Development. In that capacity, Mr. Andrew Mitrani will be responsible for growing out the business[…]

Read More

Chemical entities SHINE in the top 10 fastest-growing drugs of 2016

This week, PharmaCompass continued its analysis of the top 10 fastest-growing drugs of 2016 by sales to evaluate the drugs that registered large sales growth. Please note that these are not the top-selling drugs, but are the top 10 drugs that registered the maximum growth in global sales over 2015. Interestingly, things didn’t appear that[…]

Read More

Comedy Night Banner

LGM Pharma hosted an exclusive CPhI Comedy Night in the Good Good Comedy Theatre in Downtown Philly. The event featured a live comedy show, and plenty of food and drinks for current and prospective clients who were in town for CPhI. CPhI is the world’s leading pharmaceutical platform that brings together pharma ingredients manufacturers, suppliers[…]

Read More

Eteplirsen CAS 1173755-55-9

The U.S. Food and Drug Administration approved Eteplirsen CAS# 1173755-55-9 (marketed as Exondys 51) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the[…]

Read More